# US 2024/0279186 A1 · Cd73 compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0279186 A1
- Document ID: US20240279186A1
- Status: Published application
- Kind: A1
- Application number: 18/428,316
- Filed: 2024-01-31
- Published: 2024-08-22
- Earliest claimed: 2021-10-29
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Mark J. Bartlett; Gregory F. Chin; Michael O. Clarke; Jennifer L. Cosman; Deeba Ensan; Bindu Goyal; Stephen Ho; Richard L. Mackman; Michael R. Mish; Dustin S. Siegel; Kyle C. Tamshen; Hai Yang
- Web page: https://patentgrep.com/patent/US20240279186A1

## CPC

- C07D 247/00: Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups C07D229/00 - C07D245/00
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein is A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the various substituents are described herein.

## Claims

### Claim 1

A compound of Formula I:
Or a pharmaceutically acceptable salt thereof, wherein:
X is C or N,
Y is CH or N;
Z is C or N;
provided that one of X, Y and Z is CH or C, and two of X, Y and Z are N;
R1 is selected from H and CH2OP(O)(OH)2;
R2 is a C3-6 cycloalkyl or a 3-8 membered heterocyclyl; wherein said cycloalkyl and said heterocyclyl are substituted with one or more R4,
R3 is H or halo;
R4 is independently selected from H, halo, C1-4 alkyl, —OR5, C6-10 aryl, or 4-10 membered heteroaryl; wherein said C1-4 alkyl, C6-10 aryl, or 4-10 membered heteroaryl is optionally substituted with one or more R6;
R5 is C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, said C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C6-10 aryl, or 4-10 membered heteroaryl and is optionally substituted with one or more R6 and halo;
R6 is a C1-5 alkyl, C3-6 cycloalkyl, C1-5 alkenyl, C1-5 alkynyl, or 4-10 membered heteroaryl, said C1-s alkyl, C3-6 cycloalkyl, C1-5 alkenyl, or C1-5 alkynyl is optionally substituted with halo, and said 4-10 membered heteroaryl optionally substituted with C1-4 alkyl, or C1-4 haloalkyl.

### Claim 2 (depends on 1)

The compound of claim 1 wherein R1 is H.

### Claim 3 (depends on 1)

The compound of claim 1 wherein R1 is CH2OP(O)(OH)2.

### Claim 4 (depends on 1, 2)

The compound of claim 1 or 2, wherein R2 is a C3-6 cycloalkyl substituted with one or more R4.

### Claim 5 (depends on 1, 2)

The compound of claim 1 or 2, wherein R2 is a 3-8 membered heterocyclyl substituted with one or more R4.

### Claim 6 (depends on 1, 2, 3)

The compound of any of claims 1-3 wherein R2 is cyclopropyl substituted with one or more R4.

### Claim 7 (depends on 1, 2, 3)

The compound of claims 1-3, wherein R4 is a 4-10 membered heteroaryl, optionally substituted with one or more R6.

### Claim 8 (depends on 7)

The compound of claim 7, wherein R4 is a 4-10 membered heteroaryl, substituted with one or more R6.

### Claim 9 (depends on 8)

The compound of claim 8, wherein R4 is a 4-10 membered heteroaryl, substituted with one or more C1-5 alkyl, said C1-5 alkyl optionally substituted with halo.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R4 is a 4-10 membered heteroaryl, substituted with one or more C1-5 alkyl, said C1-5 alkyl substituted with one or more halo.

### Claim 11 (depends on 10)

The compound of claim 10, wherein R4 is a 4-10 membered heteroaryl, substituted with one or more C1-5 alkyl, said C1-5 alkyl substituted with one or more fluoro.

### Claim 12 (depends on 10, 11)

The compound of claim 10 or 11, wherein R4 is indazole, substituted with one or more C1-5 alkyl, said C1-5 alkyl substituted with one or more fluoro.

### Claim 13 (depends on 12)

The compound of claim 12, wherein R4 is indazole, substituted with one C1-5 alkyl, said C1-5 alkyl substituted with one or more fluoro.

### Claim 14 (depends on 13)

The compound of claim 13, wherein R4 is indazole, substituted with trifluoroethyl.

### Claim 15 (depends on 14)

The compound of claim 14, wherein R3 is H.

### Claim 16 (depends on 14)

The compound of claim 14, wherein R3 is halo.

### Claim 17 (depends on 16)

The compound of claim 16, wherein R3 is F.

### Claim 18 (depends on 13)

The compound of claim 13, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

### Claim 19 (depends on 1, 2, 3)

The compound of any of claims 1-3, wherein R2 is a 3-8 membered heterocyclyl; wherein said heterocylyl is substituted with one or more R4.

### Claim 20 (depends on 19)

The compound of claim 19, wherein R2 is pyrrolidinyl, substituted with one or more R4.

### Claim 21 (depends on 20)

The compound of claim 20, wherein said pyrrolidinyl is substituted with two fluoro groups and —OR5.

### Claim 22 (depends on 21)

The compound of claim 21, wherein R5 is a 4-10 membered heteroaryl and is optionally substituted with one or more R6 and halo.

### Claim 23 (depends on 20)

The compound of claim 20, wherein said pyrrolidinyl is independently substituted with four R4.

### Claim 24 (depends on 23)

The compound of claim 23, wherein said pyrrolidinyl is substituted with two methyl and two fluoro groups.

### Claim 25 (depends on 24)

The compound of claim 24, wherein said pyrrolidinyl is gem dimethyl substituted.

### Claim 26 (depends on 20)

The compound of claim 20, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A pharmaceutical composition comprising a compound of any of claims 1-26, together with a pharmaceutically acceptable carrier.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A method of treating cancer in a patient in need thereof, comprising administering to said patient a compound of claims 1-26, or a composition of claim 27.
